PGR and breast carcinoma: Development and improved sensitivity and specificity of antibodies [5] as well as the establishment of lower cut-offs of >1% have improved IHC assay performance and contributed to the identification of ER+/PR+, ER+/PR− and ER−/PR− breast cancer subtypes [6].